메뉴 건너뛰기




Volumn 10, Issue , 2015, Pages 3131-3146

Insight into molecular dynamics simulation of BRAF(V600E) and potent novel inhibitors for malignant melanoma

Author keywords

BRAF inhibitor; Docking; Ligand based; Quantitative structure activity relationship (QSAR); Structure based; Virtual screening

Indexed keywords

16BETA HYDROXY 19S VINDOLININE N OXIDE; AKNADICINE; ANTINEOPLASTIC AGENT; B RAF KINASE; B RAF KINASE INHIBITOR; UNCLASSIFIED DRUG; BRAF PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

EID: 84929501255     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S80150     Document Type: Article
Times cited : (25)

References (47)
  • 1
    • 84889606709 scopus 로고    scopus 로고
    • A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
    • Johannessen CM, Johnson LA, Piccioni F, et al. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature. 2013;504(7478):138–142.
    • (2013) Nature , vol.504 , Issue.7478 , pp. 138-142
    • Johannessen, C.M.1    Johnson, L.A.2    Piccioni, F.3
  • 2
    • 77956030786 scopus 로고    scopus 로고
    • Inhibition of mutated, activated BRAF in metastatic melanoma
    • Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809–819.
    • (2010) N Engl J Med , vol.363 , Issue.9 , pp. 809-819
    • Flaherty, K.T.1    Puzanov, I.2    Kim, K.B.3
  • 3
    • 18444374405 scopus 로고    scopus 로고
    • Mutations of the BRAF gene in human cancer
    • Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–954.
    • (2002) Nature , vol.417 , Issue.6892 , pp. 949-954
    • Davies, H.1    Bignell, G.R.2    Cox, C.3
  • 4
    • 0037228055 scopus 로고    scopus 로고
    • High frequency of BRAF mutations in nevi
    • Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33(1):19–20.
    • (2003) Nat Genet , vol.33 , Issue.1 , pp. 19-20
    • Pollock, P.M.1    Harper, U.L.2    Hansen, K.S.3
  • 5
    • 0030977312 scopus 로고    scopus 로고
    • Endothelial apoptosis in Braf-deficient mice
    • Wojnowski L, Zimmer AM, Beck TW, et al. Endothelial apoptosis in Braf-deficient mice. Nat Genet. 1997;16(3):293–297.
    • (1997) Nat Genet , vol.16 , Issue.3 , pp. 293-297
    • Wojnowski, L.1    Zimmer, A.M.2    Beck, T.W.3
  • 6
    • 4544302751 scopus 로고    scopus 로고
    • Switching on kinases: Oncogenic activation of BRAF and the PDGFR family
    • Dibb NJ, Dilworth SM, Mol CD. Switching on kinases: oncogenic activation of BRAF and the PDGFR family. Nat Rev Cancer. 2004;4(9):718–727.
    • (2004) Nat Rev Cancer , vol.4 , Issue.9 , pp. 718-727
    • Dibb, N.J.1    Dilworth, S.M.2    Mol, C.D.3
  • 7
    • 84892805414 scopus 로고    scopus 로고
    • Resistance to RAF inhibitors revisited
    • Hartsough E, Shao Y, Aplin AE. Resistance to RAF inhibitors revisited. J Invest Dermatol. 2014;134(2):319–325.
    • (2014) J Invest Dermatol , vol.134 , Issue.2 , pp. 319-325
    • Hartsough, E.1    Shao, Y.2    Aplin, A.E.3
  • 8
    • 79960027865 scopus 로고    scopus 로고
    • BRAF targeted therapy changes the treatment paradigm in melanoma
    • Ribas A, Flaherty KT. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol. 2011;8(7):426–433.
    • (2011) Nat Rev Clin Oncol , vol.8 , Issue.7 , pp. 426-433
    • Ribas, A.1    Flaherty, K.T.2
  • 9
    • 84868481873 scopus 로고    scopus 로고
    • Vemurafenib: The first drug approved for BRAF-mutant cancer
    • Bollag G, Tsai J, Zhang J, et al. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov. 2012;11(11):73–886.
    • (2012) Nat Rev Drug Discov , vol.11 , Issue.11 , pp. 73-886
    • Bollag, G.1    Tsai, J.2    Zhang, J.3
  • 10
    • 80054044954 scopus 로고    scopus 로고
    • Vemurafenib in melanoma with BRAF V600E mutation
    • author reply 1450
    • Morita H, Nagai R. Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;365(15):1448. author reply 1450.
    • (2011) N Engl J Med , vol.365 , Issue.15 , pp. 1448
    • Morita, H.1    Nagai, R.2
  • 11
    • 79959795786 scopus 로고    scopus 로고
    • BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation
    • Chapman PB, Hauschild A, Robert C, et al; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–2516.
    • (2011) N Engl J Med , vol.364 , Issue.26 , pp. 2507-2516
    • Chapman, P.B.1    Hauschild, A.2    Robert, C.3
  • 12
    • 84863116743 scopus 로고    scopus 로고
    • Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
    • Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707–714.
    • (2012) N Engl J Med , vol.366 , Issue.8 , pp. 707-714
    • Sosman, J.A.1    Kim, K.B.2    Schuchter, L.3
  • 13
    • 84864285704 scopus 로고    scopus 로고
    • Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial
    • Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358–365.
    • (2012) Lancet , vol.380 , Issue.9839 , pp. 358-365
    • Hauschild, A.1    Grob, J.J.2    Demidov, L.V.3
  • 14
    • 84861083983 scopus 로고    scopus 로고
    • RAF inhibitor dabrafenib (GSK2118436) is active in melanoma brain metastases, multiple BRAF genotypes and diverse cancers
    • Falchook G, Long G, Kurzrock R, et al. RAF inhibitor dabrafenib (GSK2118436) is active in melanoma brain metastases, multiple BRAF genotypes and diverse cancers. Lancet. 2012;379(9829):1893.
    • (2012) Lancet , vol.379 , Issue.9829 , pp. 1893
    • Falchook, G.1    Long, G.2    Kurzrock, R.3
  • 15
    • 84856190949 scopus 로고    scopus 로고
    • RAF around the edges–the paradox of BRAF inhibitors
    • Weeraratna AT. RAF around the edges–the paradox of BRAF inhibitors. N Engl J Med. 2012;366(3):271–273.
    • (2012) N Engl J Med , vol.366 , Issue.3 , pp. 271-273
    • Weeraratna, A.T.1
  • 16
    • 84864285936 scopus 로고    scopus 로고
    • BRAF inhibition and beyond in advanced melanoma
    • Margolin K. BRAF inhibition and beyond in advanced melanoma. Lancet. 2012;380(9839):320–322.
    • (2012) Lancet , vol.380 , Issue.9839 , pp. 320-322
    • Margolin, K.1
  • 17
    • 79951961755 scopus 로고    scopus 로고
    • Resistance to BRAF inhibition in melanomas
    • Solit DB, Rosen N. Resistance to BRAF inhibition in melanomas. N Engl J Med. 2011;364(8):772–774.
    • (2011) N Engl J Med , vol.364 , Issue.8 , pp. 772-774
    • Solit, D.B.1    Rosen, N.2
  • 18
    • 84861091160 scopus 로고    scopus 로고
    • Extending the reach of BRAF-targeted cancer therapy
    • Gibney GT, Sondak VK. Extending the reach of BRAF-targeted cancer therapy. Lancet. 2012;379(9829):1858–1859.
    • (2012) Lancet , vol.379 , Issue.9829 , pp. 1858-1859
    • Gibney, G.T.1    Sondak, V.K.2
  • 19
    • 78650309875 scopus 로고    scopus 로고
    • COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
    • Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010;468(7326):968–972.
    • (2010) Nature , vol.468 , Issue.7326 , pp. 968-972
    • Johannessen, C.M.1    Boehm, J.S.2    Kim, S.Y.3
  • 20
    • 77949732073 scopus 로고    scopus 로고
    • RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
    • Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464(7287):427–430.
    • (2010) Nature , vol.464 , Issue.7287 , pp. 427-430
    • Poulikakos, P.I.1    Zhang, C.2    Bollag, G.3    Shokat, K.M.4    Rosen, N.5
  • 21
    • 83455254767 scopus 로고    scopus 로고
    • RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
    • Poulikakos PI, Persaud Y, Janakiraman M, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011;480(7377):387–390.
    • (2011) Nature , vol.480 , Issue.7377 , pp. 387-390
    • Poulikakos, P.I.1    Persaud, Y.2    Janakiraman, M.3
  • 22
    • 78649436372 scopus 로고    scopus 로고
    • BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation
    • Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal. 2010;3(149):ra84.
    • (2010) Sci Signal , vol.3 , Issue.149
    • Corcoran, R.B.1    Dias-Santagata, D.2    Bergethon, K.3    Iafrate, A.J.4    Settleman, J.5    Engelman, J.A.6
  • 23
    • 78650303507 scopus 로고    scopus 로고
    • Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
    • Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468(7326):973–977.
    • (2010) Nature , vol.468 , Issue.7326 , pp. 973-977
    • Nazarian, R.1    Shi, H.2    Wang, Q.3
  • 24
    • 74849109743 scopus 로고    scopus 로고
    • Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF
    • Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell. 2010;140(2):209–221.
    • (2010) Cell , vol.140 , Issue.2 , pp. 209-221
    • Heidorn, S.J.1    Milagre, C.2    Whittaker, S.3
  • 26
    • 84856217925 scopus 로고    scopus 로고
    • Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF
    • Xing F, Persaud Y, Pratilas CA, et al. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene. 2012;31(4):446–457.
    • (2012) Oncogene , vol.31 , Issue.4 , pp. 446-457
    • Xing, F.1    Persaud, Y.2    Pratilas, C.A.3
  • 27
    • 77956513286 scopus 로고    scopus 로고
    • Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
    • Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010;467(7315):596–599.
    • (2010) Nature , vol.467 , Issue.7315 , pp. 596-599
    • Bollag, G.1    Hirth, P.2    Tsai, J.3
  • 29
    • 12144289677 scopus 로고    scopus 로고
    • Cancer Genome Project. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
    • Wan PT, Garnett MJ, Roe SM, et al; Cancer Genome Project. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116(6):855–867.
    • (2004) Cell , vol.116 , Issue.6 , pp. 855-867
    • Wan, P.T.1    Garnett, M.J.2    Roe, S.M.3
  • 30
    • 84864258996 scopus 로고    scopus 로고
    • A landscape of driver mutations in melanoma
    • Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell. 2012;150(2):251–263.
    • (2012) Cell , vol.150 , Issue.2 , pp. 251-263
    • Hodis, E.1    Watson, I.R.2    Kryukov, G.V.3
  • 31
    • 79952379083 scopus 로고    scopus 로고
    • Targeted therapy in GIST: In silico modeling for prediction of resistance
    • Pierotti MA, Tamborini E, Negri T, Pricl S, Pilotti S. Targeted therapy in GIST: in silico modeling for prediction of resistance. Nat Rev Clin Oncol. 2011;8(3):161–170.
    • (2011) Nat Rev Clin Oncol , vol.8 , Issue.3 , pp. 161-170
    • Pierotti, M.A.1    Tamborini, E.2    Negri, T.3    Pricl, S.4    Pilotti, S.5
  • 32
    • 80051625929 scopus 로고    scopus 로고
    • Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling
    • Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011;29(22):3085–3096.
    • (2011) J Clin Oncol , vol.29 , Issue.22 , pp. 3085-3096
    • Wagle, N.1    Emery, C.2    Berger, M.F.3
  • 33
    • 42949149240 scopus 로고    scopus 로고
    • Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
    • Tsai J, Lee JT, Wang W, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A. 2008;105(8):3041–3046.
    • (2008) Proc Natl Acad Sci U S A , vol.105 , Issue.8 , pp. 3041-3046
    • Tsai, J.1    Lee, J.T.2    Wang, W.3
  • 34
    • 84923917434 scopus 로고    scopus 로고
    • Molecular insight and resolution for tumors harboring the H-ras (G12V) mutation
    • Tang H-C, Chen Y-C. Molecular insight and resolution for tumors harboring the H-ras (G12V) mutation. RSC Adv. 2015;5(27):20623–20633.
    • (2015) RSC Adv , vol.5 , Issue.27 , pp. 20623-20633
    • Tang, H.-C.1    Chen, Y.-C.2
  • 35
    • 84939441929 scopus 로고    scopus 로고
    • Lipopolysaccharide-promoted proliferation of Caco-2 cells is mediated by c-Src induction and ERK activation
    • Lin TY, Fan CW, Maa MC, Leu TH. Lipopolysaccharide-promoted proliferation of Caco-2 cells is mediated by c-Src induction and ERK activation. Biomedicine (Taipei). 2015;5(1):5.
    • (2015) Biomedicine (Taipei) , vol.5 , Issue.1 , pp. 5
    • Lin, T.Y.1    Fan, C.W.2    Maa, M.C.3    Leu, T.H.4
  • 36
    • 85017728067 scopus 로고    scopus 로고
    • Sambucus williamsii induced embryonic stem cells differentiated into neurons
    • Liu SP, Hsu CY, Fu RH, et al. Sambucus williamsii induced embryonic stem cells differentiated into neurons. Biomedicine (Taipei). 2015; 5(1):3.
    • (2015) Biomedicine (Taipei) , vol.5 , Issue.1 , pp. 3
    • Liu, S.P.1    Hsu, C.Y.2    Fu, R.H.3
  • 37
    • 84904114051 scopus 로고    scopus 로고
    • Drug design of cyclin-dependent kinase 2 inhibitor for melanoma from traditional Chinese medicine
    • Tang HC, Chen CY. Drug design of cyclin-dependent kinase 2 inhibitor for melanoma from traditional Chinese medicine. Biomed Res Int. 2014;2014:798742.
    • (2014) Biomed Res Int , vol.2014 , pp. 798742
    • Tang, H.C.1    Chen, C.Y.2
  • 38
    • 84939438545 scopus 로고    scopus 로고
    • The bacterial interactions in the nasopharynx of children receiving adenoidectomy
    • Chen HX, Lai CH, Hsu HY, et al. The bacterial interactions in the nasopharynx of children receiving adenoidectomy. Biomedicine (Taipei). 2015;5(1):6.
    • (2015) Biomedicine (Taipei) , vol.5 , Issue.1 , pp. 6
    • Chen, H.X.1    Lai, C.H.2    Hsu, H.Y.3
  • 39
    • 79251561193 scopus 로고    scopus 로고
    • TCM Database@Taiwan: The world’s largest traditional Chinese medicine database for drug screening in silico
    • Chen CY. TCM Database@Taiwan: the world’s largest traditional Chinese medicine database for drug screening in silico. PLoS One. 2011;6(1):e15939.
    • (2011) Plos One , vol.6 , Issue.1 , pp. e15939
    • Chen, C.Y.1
  • 40
    • 84865435981 scopus 로고    scopus 로고
    • Development of a novel class of B-Raf(V600E)-selective inhibitors through virtual screening and hierarchical hit optimization
    • Kong X, Qin J, Li Z, et al. Development of a novel class of B-Raf(V600E)-selective inhibitors through virtual screening and hierarchical hit optimization. Org Biomol Chem. 2012;10(36):7402–7417.
    • (2012) Org Biomol Chem , vol.10 , Issue.36 , pp. 7402-7417
    • Kong, X.1    Qin, J.2    Li, Z.3
  • 41
    • 80052604878 scopus 로고    scopus 로고
    • Identification of novel BRAF kinase inhibitors with structure-based virtual screening
    • Park H, Choi H, Hong S. Identification of novel BRAF kinase inhibitors with structure-based virtual screening. Bioorg Med Chem Lett. 2011; 21(19):5753–5756.
    • (2011) Bioorg Med Chem Lett , vol.21 , Issue.19 , pp. 5753-5756
    • Park, H.1    Choi, H.2    Hong, S.3
  • 42
    • 53549110555 scopus 로고    scopus 로고
    • Identification of BRAF inhibitors through in silico screening
    • Luo C, Xie P, Marmorstein R. Identification of BRAF inhibitors through in silico screening. J Med Chem. 2008;51(19):6121–6127.
    • (2008) J Med Chem , vol.51 , Issue.19 , pp. 6121-6127
    • Luo, C.1    Xie, P.2    Marmorstein, R.3
  • 43
    • 33845730781 scopus 로고    scopus 로고
    • Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885
    • King AJ, Patrick DR, Batorsky RS, et al. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res. 2006;66(23):11100–11105.
    • (2006) Cancer Res , vol.66 , Issue.23 , pp. 11100-11105
    • King, A.J.1    Patrick, D.R.2    Batorsky, R.S.3
  • 44
    • 70349903395 scopus 로고    scopus 로고
    • Weighted equation and rules–a novel concept for evaluating protein-ligand interaction
    • Chen CY. Weighted equation and rules–a novel concept for evaluating protein-ligand interaction. J Biomol Struct Dyn. 2009;27(3):271–282.
    • (2009) J Biomol Struct Dyn , vol.27 , Issue.3 , pp. 271-282
    • Chen, C.Y.1
  • 45
    • 67649992844 scopus 로고    scopus 로고
    • Novel potent BRAF inhibitors: Toward 1 nM compounds through optimization of the central phenyl ring
    • Ménard D, Niculescu-Duvaz I, Dijkstra HP, et al. Novel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ring. J Med Chem. 2009;52(13):3881–3891.
    • (2009) J Med Chem , vol.52 , Issue.13 , pp. 3881-3891
    • Ménard, D.1    Niculescu-Duvaz, I.2    Dijkstra, H.P.3
  • 46
    • 84878775187 scopus 로고    scopus 로고
    • A novel integrated framework and improved methodology of computer-aided drug design
    • Chen CY. A novel integrated framework and improved methodology of computer-aided drug design. Curr Top Med Chem. 2013;13(9):965–988.
    • (2013) Curr Top Med Chem , vol.13 , Issue.9 , pp. 965-988
    • Chen, C.Y.1
  • 47
    • 84875592758 scopus 로고    scopus 로고
    • GROMACS 4.5: A high-throughput and highly parallel open source molecular simulation toolkit
    • Pronk S, Páll S, Schulz R, et al. GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics. 2013;29(7):845–854.
    • (2013) Bioinformatics , vol.29 , Issue.7 , pp. 845-854
    • Pronk, S.1    Páll, S.2    Schulz, R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.